FOLH1 and prostate cancer: A significant percentage of prostate cancer patients initially respond to targeted (e.g., abiraterone acetate, enzalutamide, PARP-inhibitors, and PSMA-ligand therapy) or untargeted therapies (e.g., cabazitaxel, docetaxel, and radium-223) [43].